Skip to main content

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

Written by Customer Service on . Posted in Public Companies.

Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncology

Access the segment here

CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the participation in a Virtual Investor KOL Connect segment featuring Ira S. Winer, MD, PhD, FACOG, Scientific Advisory Board Member at Ernexa Therapeutics, Professor in the Division of Gynecologic Oncology at Wayne State University School of Medicine and gynecologic oncologist at the Barbara Ann Karmanos Cancer Institute.

During the discussion, Dr. Winer provided perspective on the significant unmet need that continues to exist in ovarian cancer, limitations associated with current treatment approaches and the growing focus on overcoming immunologically “cold” tumors that remain resistant to many immune-based therapies.

The segment also explored the broader evolution of immune and cell therapies in solid tumors and discussed how scalable, off-the-shelf engineered cell therapy approaches may potentially play an increasing role in future oncology treatment paradigms by improving manufacturing scalability, expanding accessibility and offering new hope for patients with difficult-to-treat cancers.

Additionally, Dr. Winer discussed Ernexa’s ERNA-101 program, including the potential importance of activating immune responses within the tumor microenvironment and the differentiated aspects of the Company’s engineered IL-7/IL-15 fusokine-iMSC platform. The discussion highlighted the potential advantages of ERNA-101’s dual mechanism approach, including tumor microenvironment remodeling, immune activation, off-the-shelf manufacturing scalability and the potential to support broader affordability and patient access compared to more complex personalized cell therapy approaches.

The discussion also highlights the potential advantages of Ernexa’s engineered allogeneic induced mesenchymal stem cell (iMSC) platform, including the opportunity to develop scalable, off-the-shelf cell therapies designed to improve accessibility and overcome manufacturing challenges associated with traditional autologous approaches.

“Ovarian cancer remains one of the most challenging solid tumors to treat, particularly as patients progress through later lines of therapy and face increasingly limited treatment options,” said Dr. Ira Winer. “There continues to be a significant need for innovative approaches capable of addressing the immunosuppressive tumor microenvironment that characterizes many ovarian cancers. Emerging engineered cell therapy strategies designed to activate immune responses and potentially convert immunologically ‘cold’ tumors into more responsive tumors may not only create new treatment possibilities, but also potentially improve scalability and accessibility for patients in need.”

The Virtual Investor KOL Connect segment featuring Ernexa Therapeutics is now available here.

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit www.ernexatx.com.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.